about
Emerging therapeutic biomarkers in endometrial cancerAfatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.Inferring pathway dysregulation in cancers from multiple types of omic data.Endometrial stromal sarcoma metastasis to the lumbar spine and sphenoid bone.The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer[Relapsing uterine leiomyosarcoma: report of a case].erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy.Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironmentThe genomics and genetics of endometrial cancer.Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries.Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signalingMicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer.Endometrial serous carcinoma: its molecular characteristics and histology-specific treatment strategies.HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.Serous carcinoma of endometrium in combination with neuroendocrine small-cell: A case report and literature review.Activin B promotes endometrial cancer cell migration by down-regulating E-cadherin via SMAD-independent MEK-ERK1/2-SNAIL signaling.Cytoreductive surgery for advanced and recurrent endometrial cancer: a review of the literature.Emerging therapeutic targets in endometrial cancer.Uterine inversion in association with uterine sarcoma: a case report with MRI findings and review of the literature.Emerging drugs for endometrial cancer.Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroMetronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.Novel chemoembolization using calcium-phosphate ceramic microsphere incorporating TNP-470, an anti-angiogenic agent.An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: Executive summary.A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination.A case of uterine tumour resembling ovarian sex cord tumour responding to second-line, single agent anastrazole.Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
P2860
Q26865904-5261143D-6007-40F9-AB4B-3A42A28F7803Q27853078-DBD0BA22-9887-4103-8EC6-3395FA7115E6Q30980125-D0409EB4-B6E7-4CA4-88BD-2EC55FBCD952Q34069690-DACD5126-B437-4B5A-A283-60747E966EBAQ34091442-68993CD7-E4BF-437B-81E6-4E287C4FFFB5Q34634149-F019823D-2955-45CC-88B1-BA707B1FF9DFQ35094519-5EAF366E-635D-4F8F-B676-D48F11718179Q35174196-0487E805-F123-4760-88D6-64D771E63EE6Q36000984-8E6225E3-F49D-4E50-BE28-D51EA0C57B13Q36151896-1153A494-ABD5-4F47-A794-110634193757Q36245425-DA0C2AB7-6EF8-4464-9D91-841455608A91Q36510153-AC2FBB45-593B-4C1C-BBE0-FEF496479B9BQ36544657-13BE0B90-9F40-439C-B7EA-4EB473FEEA3AQ36827700-C0C87202-4825-4F5F-A585-9332E967E646Q37017041-983FF3ED-9E45-4148-AE2A-5BADDA43BDC8Q37080967-EDA1D4B3-F97A-48D3-BFD9-528F33BB2DD9Q37146313-FBDA000A-13FB-44D1-8297-7E6591197CC3Q37457788-CFECDB91-B90F-4B02-9C7D-D7DD2B04EFE1Q37544846-56ADFBF8-543E-4977-9DA1-F9F902310C1DQ37827340-C01DE68A-F92D-4D3F-B74C-9286DE982738Q37989278-730311E6-73BA-44DD-8674-80FDBB04AB9BQ38261469-B961B59D-D72E-42B9-9D74-F302B95C5D05Q38911022-057F8597-B08F-4386-B24D-2BAD2B27759EQ39612504-88EDE15C-992A-4338-B0CB-58E1D9DDCE0EQ39746869-BF8C0495-147F-487F-8F64-6756E2DD2BC2Q40990402-DB7698C4-BD85-47EF-9F84-DFBFFFF6A25FQ42045828-112470B4-5712-4A7E-8D8B-DA67ED5B3A4EQ43273518-12D01C7E-387D-443D-8BF3-FE2C5DC36270Q44522454-0C6E9F27-E595-475B-A863-28A787E048B0Q51062353-A4FB989A-3D04-444F-95AF-BD35E5F01173Q57169683-719A5D2D-FAAE-4B22-A4D1-C3AB015FF1C7
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Rare uterine cancers.
@ast
Rare uterine cancers.
@en
Rare uterine cancers.
@nl
type
label
Rare uterine cancers.
@ast
Rare uterine cancers.
@en
Rare uterine cancers.
@nl
prefLabel
Rare uterine cancers.
@ast
Rare uterine cancers.
@en
Rare uterine cancers.
@nl
P2093
P1433
P1476
Rare uterine cancers.
@en
P2093
Anthony C Montag
Gini F Fleming
Martee L Hensley
Sheetal Acharya
P304
P356
10.1016/S1470-2045(05)70463-0
P577
2005-12-01T00:00:00Z